Drug Discovery and Development for Heart Failure Using Multi-Omics Approaches DOI Open Access
Danielle Rasooly, Alexandre C. Pereira, Joseph Jacob

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(6), С. 2703 - 2703

Опубликована: Март 17, 2025

Heart failure (HF) is a complex, heterogeneous syndrome with rising prevalence and high morbidity mortality. The pathophysiology diverse etiologies of HF present significant challenges for developing effective therapies. Omics technologies—including genomics, proteomics, transcriptomics, metabolomics, epigenomics—have reshaped our understanding at the molecular level, uncovering new biomarkers potential therapeutic targets. also enable insights into individualized treatment responses, risks adverse drug effects, patient stratification clinical trials. This review explores how multi-omics can enhance heart discovery development across all stages pipeline: (1) target selection lead identification, (2) preclinical studies, (3) By integrating omics approaches throughout process, we accelerate more personalized therapies failure.

Язык: Английский

Drug Discovery and Development for Heart Failure Using Multi-Omics Approaches DOI Open Access
Danielle Rasooly, Alexandre C. Pereira, Joseph Jacob

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(6), С. 2703 - 2703

Опубликована: Март 17, 2025

Heart failure (HF) is a complex, heterogeneous syndrome with rising prevalence and high morbidity mortality. The pathophysiology diverse etiologies of HF present significant challenges for developing effective therapies. Omics technologies—including genomics, proteomics, transcriptomics, metabolomics, epigenomics—have reshaped our understanding at the molecular level, uncovering new biomarkers potential therapeutic targets. also enable insights into individualized treatment responses, risks adverse drug effects, patient stratification clinical trials. This review explores how multi-omics can enhance heart discovery development across all stages pipeline: (1) target selection lead identification, (2) preclinical studies, (3) By integrating omics approaches throughout process, we accelerate more personalized therapies failure.

Язык: Английский

Процитировано

0